Dr. James I. Swischuk

The decrease was statistically significant, Dr. James I. Swischuk said on Tuesday at the 11th annual Advanced Interventional Management Symposium in New York City.
...
"A trend of decreased thrombolytic efficacy at 0.1 unit per hour of reteplase suggests that reteplase at 0.2 unit per hour or higher with or without abciximab provides the best balance of efficacy and safety for acute occlusions," said Swischuk, a clinical associate professor of radiology at the University of Illinois College of Medicine.

Larger studies need to be conducted to confirm these results, Swischuk said.

Dr. James Swischuk of the University of Illinois, Peoria, presented a review of "Arterial Lysis Techniques" in which he highlighted the EKOS® EndoWaveTM system. In his presentation he characterized the evolution of treatment for acute peripheral arterial thrombosis from the early nineties to today when newer therapeutic agents, devices and infusion systems contribute to more patients with acute ischemia being candidates for endovascular forms of treatment. Many of the new devices have made very positive strides in rapidly restoring blood flow to the affected limb.

Jim Swischuk, M.D.University of Illinois College of Medicine at Peoria

Guest Faculty